Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Singular Genomics Systems (OMIC)
NASDAQ:OMIC
reports
Singular Genomics Systems (OMIC) Stock Price & Analysis
55 Followers
OMIC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.80 - $10.29
Previous Close$2.77
Volume63.23K
Average Volume (3M)130.92K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$263.84M
Total Debt (Recent Filing)$59.05M
Price to Earnings (P/E)-2.2
Beta1.21
Next EarningsMar 01, 2023
EPS Estimate-$0.42
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$2.75
EPS (TTM)-1.25
Shares Outstanding71,396,110
R-Squared0.07
Standard Deviation0.18
10 Day Avg. Volume140,049
30 Day Avg. Volume130,921
Price to Book (P/B)0.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside-0.72% Downside
Rating ConsensusHold
Alpha-0.11
Number of Analyst Covering2
Singular Genomics Systems News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OMIC FAQ
What was Singular Genomics Systems’s price range in the past 12 months?
Singular Genomics Systems lowest stock price was $1.80 and its highest was $10.29 in the past 12 months.
What is Singular Genomics Systems’s market cap?
Currently, no data Available
When is Singular Genomics Systems’s upcoming earnings report date?
Singular Genomics Systems’s upcoming earnings report date is Mar 01, 2023 which is in 32 days.
How were Singular Genomics Systems’s earnings last quarter?
Singular Genomics Systems released its earnings results on Nov 07, 2022. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.075.
Is Singular Genomics Systems overvalued?
According to Wall Street analysts Singular Genomics Systems’s price is currently Overvalued.
Does Singular Genomics Systems pay dividends?
Singular Genomics Systems does not currently pay dividends.
What is Singular Genomics Systems’s EPS estimate?
Singular Genomics Systems’s EPS estimate is -$0.42.
How many shares outstanding does Singular Genomics Systems have?
Singular Genomics Systems has 71,396,110 shares outstanding.
What happened to Singular Genomics Systems’s price movement after its last earnings report?
Singular Genomics Systems reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went down -5.804%.
Which hedge fund is a major shareholder of Singular Genomics Systems?
Among the largest hedge funds holding Singular Genomics Systems’s share is Deerfield Management Company, LP. It holds Singular Genomics Systems’s shares valued at 18M.
---
Singular Genomics Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.75
$2.75
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.44%
12-Months-Change
Fundamentals
Return on Equity
-28.47%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Singular Genomics Systems
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Integrated Solution is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
---
---